Related Experiment Video
Updated: Apr 9, 2026
Multi-Tracer Studies of Brain Oxygen and Glucose Metabolism Using a Time-of-Flight Positron Emission Tomography-Computed Tomography Scanner
Published on: June 7, 2024
Pediatric microdose and microtracer studies using 14C in Europe
M A Turner1, M G Mooij2, W H J Vaes3
1Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Insights
Pediatric drug studies face challenges, but microdose and microtracer methods using carbon-14 labeled probes offer a promising approach for evaluating drug safety and efficacy in children.
Area of Science:
- Pediatric pharmacology
- Radiopharmaceutical research
Background:
- Significant knowledge gaps exist regarding the safety and efficacy of medications in pediatric populations.
- Ethical, practical, and scientific hurdles complicate pediatric drug development.
- A lack of child-adapted innovative methodologies hinders drug evaluation for children.
Purpose of the Study:
- To present successful European experiences with pediatric microdose and microtracer studies.
- To illustrate the strengths and limitations of these specialized study designs.
Main Methods:
- Utilized carbon-14 (14C)-labeled probes for microdose and microtracer studies in pediatric populations.
- Applied these methodologies within a European research context.
Main Results:
- Demonstrated the successful application of pediatric microdose and microtracer studies.
- Provided insights into the practical strengths and limitations of these approaches in children.
Conclusions:
- Pediatric microdose and microtracer studies using 14C-labeled probes are viable methods for drug evaluation.
- These approaches offer valuable data on drug efficacy and safety in pediatric populations despite existing challenges.
Abstract:
Important information gaps remain on the efficacy and safety of drugs in children. Pediatric drug development encounters several ethical, practical, and scientific challenges. One barrier to the evaluation of medicines for children is a lack of innovative methodologies that have been adapted to the needs of children. This article presents our successful experience of pediatric microdose and microtracer studies using (14) C-labeled probes in Europe to illustrate the strengths and limitations of these approaches.
